IVVD Doubled on Clinical Trial Results
Invivyd, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. Earnings in 48 days. Avg 30D Vol at 24.67M Current Vol at 74.70M
Can this break and retest $2.35? If it does analyst have targets as high as $10. GL!
Can this break and retest $2.35? If it does analyst have targets as high as $10. GL!
Aviso legal
As informações e publicações não devem ser e não constituem conselhos ou recomendações financeiras, de investimento, de negociação ou de qualquer outro tipo, fornecidas ou endossadas pela TradingView. Leia mais em Termos de uso.